Lattice is an emerging personalized/precision medicine leader in the field of cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration. Lattice develops and processes biologic products to domestic and international markets.
More than a million allografts (bone, ligament, cartilage, tendon or skin transplanted from one person to another) are used in the United States, alone, each year for a wide variety of surgical applications ranging from reconstruction to orthopedic, spine, sports medicine, cardiac, dental, and cosmetic procedures. Allograft transplantation has been used for decades to help everyone from athletes who need knee reconstruction to patients suffering from back pain and cancer patients who undergo surgery. These operations rely on the invaluable gift of donors, but not all allograft procedures are successful.
Lattice Biologics is passionately committed to honoring the gift of tissue donation and “stacking the deck” to maximize all patients’ results which is why we have devoted extensive ongoing research to improve the surgical outcomes for allograft recipients. This was the impetus for developing Next Generation Allograft Technology.
Unlike the undirected scaffold allograft products currently available on the market, Lattice Biologics’ Next Generation Allografts drastically improve post-surgical healing and reduce recovery time for allograft recipients.
Read on to learn more about this technology and how Lattice is utilizing it to improve patient outcomes.